Neuroscience
| CSTコード |
包装 |
希望納入価格（円） |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #2274 | 100 μL | 46,000 | |
|
推奨プロトコール
最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注：各製品に最適化されたプロトコールをリンクしています。
| | |
-
2274:
-
Immunoprecipitation
Western Blotting
| 用途（希釈倍率） | |
| ウエスタンブロッティング(1:1,000)、免疫沈降（1:50） |
| 特異性・感度 | |
| 内在性レベルのMELK タンパク質を検出します。 |
| 使用抗原 | |
| ヒトのMELK タンパク質のC 末端近傍領域（合成ペプチド） |
Western Blotting
Western blot analysis of extracts of jurkat and K562 cells, using MELK Antibody.
MELK (Maternal Embryonic Leucine zipper Kinase, MPK38, KIAA0175) is a member of the Snf1/AMPK related kinase family. It is implicated in stem cell renewal, cell cycle progression and pre-m-RNA splicing (1,2,3). MELK is also a marker for self-renewing multipotent neural progenators, and may function in embryonic and postnatal forebrain development (4). While other members of this kinase family are activated by LKB1 and CAMKII mediated phosphorylation of the T-loop, MELK is not (5,6,7). Regulation of activation appears complex since MELK overexpressed in mammalian cells is inactive (7). Some evidence suggests that activation occurs through autophosphorylation of Thr167 and Ser171, although a number of additional autophosphorylation sites have been suggested (8). Recently, phosphorylations of Thr449, Thr451 and Thr481 have been specifically detected during mitosis, and are thought to occur via MPF and MAPK pathways (9). MELK has broad substrate specificity in vitro: substrates include ZPR9 (10), NIPP1 (11) and cdc25B (12), although the significance of MELK mediated phosphorylation of these proteins is unclear.Finally, recent studies on human tumor samples and cell lines suggest that MELK expression is frequently elevated in cancer relative to normal tissues (13). MELK may provide a growth advantage for neoplastic cells, and may be a potential target for anti-cancer therapies.
-
Heyer, B.S. et al. (1999)
Dev. Dyn.
215, 344-51.
-
Davezac, N. et al. (2002)
Oncogene
21, 7630-41.
-
Vulsteke, V. et al. (2004)
J. Biol. Chem.
279, 8642-7.
-
Nakano, I. et al. (2005)
J. Cell Biol.
170, 413-27.
-
Tassan, J.P. and Le Goff, X. (2004)
Biol. Cell
96, 193-9.
-
Woods, A. et al. (2003)
Curr. Biol.
13, 2004-8.
-
Lizcano, J.M. et al. (2004)
EMBO J.
23, 833-43.
-
Beullens, M. et al. (2005)
J. Biol. Chem.
280, 40003-11.
-
Badouel, C. et al. (2006) Cell Cycle. 5, 883-889.
-
Seong, H.A. et al. (2002)
Biochem. J.
361, 597-604.
-
Vulsteke, V. et al. (2004)
J. Biol. Chem.
279, 8642-7.
-
Davezac, N. et al. (2002)
Oncogene
21, 7630-41.
-
Gray, D. et al. (2005)
Cancer Res.
65, 9751-61.
